Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation

The complexity of interpreting genetic variants often leads to delays, inconsistencies, and reduced confidence in reporting.

Oxford Gene Technology (OGT, Oxfordshire, UK), a Sysmex Group company and a global leader in genomic research and diagnostic solutions, and QIAGEN Digital Insights (QDI, Redwood City, CA, USA), a leading provider of genomic interpretation and analysis tools, have entered into a new co-marketing and distribution partnership.

The partnership expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq NGS panels. Purpose-built for variant interpretation and clinical reporting, QCI Interpret delivers AI-powered, expert-curated classifications along with oncologist-reviewed summaries and transparent evidence links. Through this collaboration, SureSeq NGS panel users gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.

QDI has built the world’s largest expert-curated knowledge base of genomic and bioinformatic content, serving as the foundation of QCI Interpret. By combining the clinical precision of expert (MD/PhD) curation with the speed and scalability of AI-powered automation, QCI Interpret enables labs to deliver high-confidence variant interpretation and reporting. QCI Interpret empowers SureSeq customers with transparent variant classifications, oncologist-reviewed summaries, and on-demand interpretations—streamlining the path from sequencing to final report.

OGT’s suite of SureSeq NGS products has been developed with superior hybridization-based detection capabilities to ensure clinical research labs effortlessly achieve comprehensive genomic profiling of their samples and minimize the risk of missing variants. Combined with the unmatched accuracy and consistency of QIAGEN’s proprietary software, labs gain access to an end-to-end workflow for faster, better-informed, and more confident insights.

“We are delighted to be partnering with QIAGEN Digital Insights to allow OGT’s customers to package their SureSeq NGS panels with QIAGEN Digital Insights tertiary analysis software, creating an end-to-end NGS workflow with access to the world’s largest knowledge base, increasing customers' confidence in variant classification,” said Gareth Thomson, Executive Vice President of Commercial Operations at OGT. “This partnership is an important demonstration of OGT’s commitment to providing the most relevant and impactful oncology insights.”

“We are pleased to partner with OGT to deliver an even greater impact to labs worldwide,” added Nitin Sood, Senior Vice President and head of Life Sciences at QIAGEN. “This collaboration reinforces QIAGEN Digital Insights’ global leadership in variant interpretation to deliver scalable, collaborative and cutting-edge solutions for precision medicine. As labs face mounting challenges with the complexity and volume of NGS testing, QDI is uniquely positioned to support SureSeq workflows with transparent variant classifications, oncologist-reviewed insights, and flexible reporting. This helps customers to scale confidently, reduce turnaround times, and improve outcomes for patients.”

Related Links:
OGT
QDI